Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | FOS | P01100 | 1/20 | 0.44 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6232135 | 1.00 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL6232140 | 1.00 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL9023562 | 0.89 | ALDH1A1 (0.55) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL9023565 | 0.89 | ALDH1A1 (0.55) | MAPTMEN1KMT2AALDH1A1LMNA | |
| Benzene SCHEMBL27424700 | 0.89 | ALDH1A1 (0.55) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3540128 | 0.88 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3540131 | 0.88 | MAPT (0.50) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL7379252 | 0.87 | SMN1; SMN2 (0.46) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL13082048 | 0.85 | TLR4 (0.47) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL25410057 | 0.85 | KMT2A (0.51) | MAPTMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| WO-2007146136-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| EP-0888301-B1 | MCBI ANALOGS OF CC-1065 AND THE DUOCARMYCINS | SCRIPPS RESEARCH INST (US) | 2005-08-10 | — | — | EP | disclosed |
| US-5985908-A | MCBI (7-METHOXY-1,2,9A-TETRA-HYDROCYCLOPROPA(C)BENZ(E)INDOL-4-ONE) IS EMPLOYABLE AS A DNA ALKYLATING AGENT AND CAN BE INCORPORATED INTO ANALOGS OF CC-1065 AND THE DUOCARMYCINS FOR | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-11-16 | — | — | US | disclosed |
| US-5308852-A | Cardiovascular disorders | MERCK FROSST CANADA, INC. (CA) | 1994-05-03 | — | — | US | disclosed |
| EP-0579304-A1 | Heteroarylnaphthalenes as inhibitors of leukotriene biosynthesis | MERCK FROSST CANADA INC. (CA) | 1994-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN1, KCNN3, KCNN2 | MAPT 1089/4885MEN1 1259/4885KMT2A 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.